Safety Study of ADV-specific T-cells in Paediatric Patients Post Allo-HSCT (ASPIRE)
Phase I/II Study Investigating the Safety of ADV Specific T Cells in High-risk Paediatric Patients Post Allo-HSCT to Treat ADV Reactivation
Sponsor: Cell Medica Ltd
A PHASE1/PHASE2 clinical study on ADV Infection Post Allo-HSCT, this trial is completed. The trial is conducted by Cell Medica Ltd and has accumulated 6 data snapshots since 2012. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
First recorded
Dec 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cell Medica Ltd
- Technology Strategy Board, United Kingdom
For direct contact, visit the study record on ClinicalTrials.gov .